Valsartan Teva Dosage/Direction for Use

Hypertension: The recommended dose of Valsartan Teva is 80 mg once daily for most patients. The antihypertensive effect is substantially present within 2 weeks and maximal effects are seen after 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg. Further blood pressure reduction may be achieved by adding in a thiazide diuretic.
Valsartan Teva may also be administered with other antihypertensive agents.
Recent-myocardial infarction: Therapy may be initiated as early as 12 hours after a myocardial infarction in clinically stable patients. After an initial dose of 20 mg twice daily, valsartan therapy should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible tablet.
The target maximum dose is 160 mg twice a day. It is generally recommended that patients have reached an 80 mg dose twice a day, two weeks after the treatment was initiated and that a maximum dose, 160 mg twice a day has been reached after three months, based on the patient's tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dosage reduction.
Valsartan may be used in patients treated with other post-myocardial infarction therapies, e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins and diuretics. Concurrent use of ACE-inhibitors is not recommended (see Precautions, Adverse Reactions and Pharmacology: Pharmacodynamics under Actions).
Evaluation of post-myocardial infarction patients should always include evaluation of renal function.
Additional information on special populations: Elderly: No dose adjustment is required in elderly patients.
Use in renal impairment: No dosage adjustment is required for patients with a creatinine clearance >10 ml/min (see Precautions and Pharmacology: Pharmacokinetics under Actions).
For patients with severe renal impairment valsartan is contraindicated (see Contraindications).
Use in patients with mild to moderate hepatic impairment: In patients with mild to moderate hepatic impairment without cholestasis the dose of valsartan should not exceed 80 mg (see Precautions). Patients with severe hepatic impairment, cirrhosis or biliary obstruction should not use Valsartan Teva (see Contraindications).
Use in children and adolescents: Valsartan is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Method of administration: The tablets should be swallowed with a sufficient amount of fluid (e. g. one glass of water). The tablet can be taken with or without food.